{"publication_id":"6a95d805-9bed-4d50-9674-754d8b52c1ea","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application","doi":"10.4093/dmj.2025.0220","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback","doi":"10.34067/kid.0000000000000425","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","doi":"10.3389/fphar.2024.1364110","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","doi":"10.1136/bmjdrc-2023-003666","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM‐HET3 mice","doi":"10.1111/acel.13653","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study","doi":"10.1038/s41591-022-02120-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"The Effects of SGLT2 Inhibitors on Lipid Metabolism","doi":"10.3390/metabo11020087","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy","doi":"10.3389/fphar.2021.664181","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure","doi":"10.1161/jaha.120.018298","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?","doi":"10.3390/diseases8020014","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Canagliflozin extends life span in genetically heterogeneous male but not female mice","doi":"10.1172/jci.insight.140019","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor","doi":"10.1007/s40262-020-00875-1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Empagliflozin Increases Cardiac Energy Production in Diabetes","doi":"10.1016/j.jacbts.2018.07.006","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects","doi":"10.1681/asn.2016030278","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}